Cancer
NICE rejects PharmaMar’s ovarian cancer drug Yondelis
March 14, 2011Sales and Marketing Cancer, NICE, PharmaMar, Trabectedin, Yondelis, ovarian cancer
NICE has rejected PharmaMar’s ovarian cancer drug in final draft guidance due to a lack of ‘robust’ data. Yondelis (trabectedin) …
Sanofi lung cancer drug fails in late-stage trial
March 11, 2011Research and Development Cancer, NSCLC, Regeneron, Sanofi-Aventis, aflibercept, non-small cell lung cancer
Sanofi-Aventis’ lung cancer drug aflibercept has failed to meet its primary endpoint in a phase III trial. The late-stage VITAL …
Eisai prepares ground for Halaven’s European launch
March 7, 2011Sales and Marketing Cancer, EMBRACE, Eisai, Halaven, advanced breast cancer, breast cancer, eribulin
Eisai has published further details of a phase III trial of its first-in-class chemotherapy drug Halaven ahead of its hoped-for …
Avastin’s breast cancer use to continue in Europe
March 2, 2011Sales and Marketing CHMP, Cancer, European Commission, Roche, avastin, bevacizumab, breast cancer, docetaxel, paclitaxel
Roche’s Avastin will remain on the market as a treatment for breast cancer, but only in combination with paclitaxel, the …
Glioblastoma vaccine enters phase II
February 24, 2011Research and Development Cancer, GBM, ImmunoCellular Therapeutics, oncology
The first patient has been enrolled in a phase II trial of ICT-107, a cancer vaccine candidate for the treatment …
No magic bullet, but a growing arsenal against lung cancer
February 23, 2011Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer
A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …
NICE yes for Votrient, no to Avastin
February 23, 2011Sales and Marketing Cancer, GSK, GlaxoSmithKline, Kidney cancer, NICE, Roche, avastin, bevacizumab, breast cancer
NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient on the same day it gave a final negative decision to Roche’s …
Astellas to commercialise new kidney cancer drug in Europe
February 21, 2011Sales and Marketing Astellas, Aveo Pharmaceuticals, Cancer, Kidney cancer, rcc, renal cell carcinoma, tivozanib
Astellas and Aveo Pharmaceuticals are to commercialise Aveo’s investigational kidney cancer drug tivozanib in Europe and the US. Aveo is …
Melanoma: intense competition to be the next milestone treatment
February 9, 2011Research and Development BRAF V600 mutation, Cancer, Tasigna, cancer research, melanoma, tremelimumab
A flurry of new data has emerged in the recent months from an industry-wide pipeline of cancer drugs which could …
Early diagnosis key to UK cancer ambition
February 8, 2011Cancer, NHS, NICE
A series of quality standards on cancer care is to be drawn up by NICE as part of a new …
Roche eyes ovarian cancer expansion for Avastin
February 8, 2011Sales and Marketing Cancer, Roche, avastin, bevacizumab, ovarian cancer
Roche has submitted an EU marketing authorisation for Avastin for the treatment of ovarian cancer and plans to file the …
Late-stage blow to AstraZeneca’s prostate cancer drug
February 7, 2011Research and Development AstraZeneca, Cancer, prostate cancer, zibotentan
A late-stage trial of AstraZeneca’s oral prostate cancer drug zibotentan has been halted after it failed to meet its primary …
Digital Pharma: Merck Serono launches campaign for cancer carers
February 4, 2011Medical Communications Cancer, Digital Pharma blog, Merck Serono, disease awareness campaigns, lung cancer
Merck Serono has launched an educational lung cancer website for the ‘people behind the patients’ in Europe. Unveiled to coincide …
Sanofi buys into cancer antibody research
January 26, 2011Research and Development Cancer, Oxford Biotherapeutics, Sanofi, Sanofi-Aventis, antibody drug conjugate, cancer research
Sanofi-Aventis has bought a global licence to develop and commercialise one of Oxford BioTherapeutics’ (OBT) oncology programmes. For an undisclosed …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
